Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC)

Date

03 Mar 2020

Session

Proffered Papers 2: Individual targets

Presenters

Philippe Bedard

Citation

Annals of Oncology (2020) 31 (suppl_1): S8-S10. 10.1016/annonc/annonc82

Authors

P. Bedard1, M. Mates2, K.A. Gelmon3, J. Hilton4, D. Tu5, I. Li1, L. Rastgou6, N. Drummond-Ivars4, J. Edwards2, D. Warr1, C. Lohrisch7, X. song4, A. Srikanthan4, A. Robinson2, L. Hagerman5, L.K. Seymour8, M. Rushton8, D.W. Cescon1

Author affiliations

  • 1 Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 2 Cancer Centre of Southeastern Ontario, K7L 5P9 - Kingston/CA
  • 3 Medical Oncology Department, BC Cancer, V5Z 4E6 - Vancouver/CA
  • 4 Medical Oncology Dept, The Ottawa Hospital Regional Cancer Centre, K1H 8L6 - Ottawa/CA
  • 5 Canadian Clinical Trials Group, Kingston/CA
  • 6 Medical Oncology Department, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 7 BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 8 Ind Program, Canadian Cancer Trials Group, K7L 3N6 - Kingston/CA
More

Resources

CFI-402257 is a selective oral inhibitor of TTK protein kinase, a critical regulator of the mitotic spindle assembly checkpoint. TTK is overexpressed in breast cancer (BC); CFI-402257 has anti-proliferative and cytotoxic activity as monotherapy. Synergy has been identified between TTK inhibitors and taxanes; CFI-402257 enhances the antitumor activity of paclitaxel in BC xenograft models.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings